Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.